相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Thomas E. Stinchcombe et al.
JAMA ONCOLOGY (2019)
1480OCTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
Q Zhou et al.
ANNALS OF ONCOLOGY (2019)
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol
Takashi Ninomiya et al.
CLINICAL LUNG CANCER (2019)
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
Jennifer W. Carlisle et al.
FUTURE ONCOLOGY (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
Overview of current systemic management of EGFR-mutant NSCLC
W. -H. Hsu et al.
ANNALS OF ONCOLOGY (2018)
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma
Po-Hao Feng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.
Noboru Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Gonzalo Recondo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
Terufumi Kato et al.
DRUG SAFETY (2018)
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
Chinami Masuda et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
Xinyang Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
S. Lu et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis
Miaomiao Sheng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification
Koh Furugaki et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
E. C. Martino et al.
CELL DEATH DISCOVERY (2016)
A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
Eiki Ichihara et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
Heyan Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto et al.
LANCET ONCOLOGY (2014)
Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells
Koh Furugaki et al.
LUNG CANCER (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model
Hiromi Hayakawa et al.
CANCER SCIENCE (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Jonathan Welti et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Barbara Sennino et al.
CANCER DISCOVERY (2012)
Basic and Therapeutic Aspects of Angiogenesis
Michael Potente et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2011)
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
Roy S. Herbst et al.
LANCET (2011)
Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
Annette K. Larsen et al.
PHARMACOLOGY & THERAPEUTICS (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo
Eiki Ichihara et al.
CANCER RESEARCH (2009)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov et al.
CLINICAL CANCER RESEARCH (2009)
Revacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy
Paxton V. Dickson et al.
CLINICAL CANCER RESEARCH (2007)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
F Ciardiello et al.
CLINICAL CANCER RESEARCH (2004)
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-II
H Wildiers et al.
BRITISH JOURNAL OF CANCER (2003)
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
L Yen et al.
ONCOGENE (2000)
分享论文
